Evaluation of integrin αvβ3-targeted imaging for predicting disease progression in patients with high-risk differentiated thyroid cancer (using 99mTc-3PRGD2)

Table 3 Multivariate Cox regression analysis for progression-free survival in high-risk DTC patients

Variable	Number of patients	Progression (%)	HR (95% CI)	P
Age
< 55	23	39.1	1	0.565
≥ 55	10	60.0	0.47 (0.04–6.17)	0.565
Sex
Female	19	52.6	1	0.776
Male	14	35.7	0.83 (0.22–3.10)	0.776
Pathologic type
Papillary	29	41.4	1	0.440
Follicular	4	75.0	2.33 (0.27–20.04)	0.440
Stage
I + II	27	40.7	1	0.839
III + IV	6	66.7	1.25 (0.15–10.79)	0.839
TSH-stimulated Tg
≤ 50	13	30.8	1	0.210
> 50	19	52.6	2.60 (0.58–11.57)	0.210
^99mTc-3PRGD₂ uptake by metastases
Not avid	8	12.5	1	0.043^*
Avid	25	56.0	9.47 (1.08–83.20)	0.043^*
¹³¹I uptake by metastases
Not avid	19	52.6	1	0.101
Avid	14	35.7	0.30 (0.07–1.26)	0.101

Abbreviations: HR hazard ratio, CI confidence interval, Tg thyroglobulin, TSH thyroid stimulating hormone
^*P < 0.05

ISSN: 1470-7330